CN Patent

CN109320509A — Fxr受体激动剂

Assigned to Xuanzhu Biopharmaceutical Co Ltd · Expires 2019-02-12 · 7y expired

What this patent protects

本发明属于医药技术领域，具体涉及式(I)所示的化合物、其药学上可接受的盐、酯或其立体异构体，R 1 、R 2 、R 3 、R 4 、W、A、Z、E、X、Y、n如说明书及权利要求书中所定义；本发明还涉及这些化合物的制备方法、药物制剂及在用于制备治疗和/或预防由FXR受体介导的非酒精性脂肪肝、原发性胆汁性肝硬化、脂质代谢紊乱、糖尿病并发症及恶性肿瘤等相关疾病的药物中的应用。

USPTO Abstract

本发明属于医药技术领域，具体涉及式(I)所示的化合物、其药学上可接受的盐、酯或其立体异构体，R 1 、R 2 、R 3 、R 4 、W、A、Z、E、X、Y、n如说明书及权利要求书中所定义；本发明还涉及这些化合物的制备方法、药物制剂及在用于制备治疗和/或预防由FXR受体介导的非酒精性脂肪肝、原发性胆汁性肝硬化、脂质代谢紊乱、糖尿病并发症及恶性肿瘤等相关疾病的药物中的应用。

Drugs covered by this patent

Patent Metadata

Patent number
CN109320509A
Jurisdiction
CN
Classification
—
Expires
2019-02-12
Drug substance claim
No
Drug product claim
No
Assignee
Xuanzhu Biopharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.